title: Consensus panel's assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics.
abstract: In this summary article, the authors discuss the characteristics of abobotulinumtoxinA, incobotulinumtoxinA, and onabotulinumtoxinA. With 3 neuromodulators available in the US market, comparisons between and among products will invariably be made, so arguments for the most effective facial aesthetic uses of each neuromodulator are presented. Topics addressed in this article include patient expectations, toxin reconstitution and preparation, patient positioning, differences among products, the role of complexing proteins, and dosing and injection strategies. Recommendations are also provided by treatment area.
authors.affiliation: Private practice in New York, New York, USA. lorenc@lorenc.com
authors.forename: Z Paul
authors.initials: ZP
authors.lastname: Lorenc
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Kenkel
authors.forename: Steven
authors.initials: S
authors.lastname: Fagien
authors.forename: Haideh
authors.initials: H
authors.lastname: Hirmand
authors.forename: Mark S
authors.initials: MS
authors.lastname: Nestor
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Sclafani
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Sykes
authors.forename: Heidi A
authors.initials: HA
authors.lastname: Waldorf
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005145:Face; D006801:Humans; D012060:Rejuvenation; D015595:Skin Aging
chemical_list: D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA; C545476:incobotulinumtoxinA